We aimed to examine if WEE1 inhibition could elicit anti-tumor effects and its underlying mechanisms, with the hope of introducing a novel postoperative treatment strategy for endometrial cancer patients, particularly those experiencing recurrence. This evidence concerns the gene WEE1 and endometrial cancer.